Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

INTRODUCTION: OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA) was a randomized, double-blind comparison of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch in patients with mild-to-moderate Alzheimer’s disease who declined despite open-label treatment with 9.5 mg/24 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Molinuevo, José L, Frölich, Lutz, Grossberg, George T, Galvin, James E, Cummings, Jeffrey L, Krahnke, Tillmann, Strohmaier, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353453/
https://www.ncbi.nlm.nih.gov/pubmed/25755685
http://dx.doi.org/10.1186/s13195-014-0088-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353453/
https://www.ncbi.nlm.nih.gov/pubmed/25755685
http://dx.doi.org/10.1186/s13195-014-0088-8

Ejemplares similares